{"id":22073,"date":"2025-05-05T04:30:00","date_gmt":"2025-05-05T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-participera-a-la-conference-citizens-jmp-life-sciences\/"},"modified":"2025-05-06T22:33:04","modified_gmt":"2025-05-07T02:33:04","slug":"dbv-technologies-participera-a-la-conference-citizens-jmp-life-sciences","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-participera-a-la-conference-citizens-jmp-life-sciences\/","title":{"rendered":"DBV Technologies participera \u00e0 la conf\u00e9rence Citizens JMP Life Sciences"},"content":{"rendered":"<div class=\"pr-date-globe\">May 05, 2025 16:30 ET<\/div>\n<p align=\"right\">Ch\u00e2tillon, France, le 5 mai (22\u00a0:30 CEST) 2025<\/p>\n<p align=\"justify\"><strong>DBV Technologies participera \u00e0 la conf\u00e9rence Citizens JMP Life Sciences <\/strong><\/p>\n<p align=\"justify\">DBV Technologies (Euronext : DBV \u2013 ISIN : FR0010417345 \u2013 Nasdaq Stock Market : DBVT), soci\u00e9t\u00e9 biopharmaceutique en phase clinique, annonce aujourd&rsquo;hui que Daniel Tass\u00e9, Directeur G\u00e9n\u00e9ral, participera \u00e0 une discussion \u00ab\u00a0fireside chat\u00a0\u00bblors de la conf\u00e9rence Citizens JMP Life Sciences, le mercredi 7 mai 2025 \u00e0 11h00 (heure de l&rsquo;Est), \u00e0 New York.<\/p>\n<p align=\"justify\">Une webdiffusion en direct du \u00ab\u00a0fireside chat\u00a0\u00bb est accessible <a title=\"ici\" href=\"https:\/\/wsw.com\/webcast\/jmp65\/register.aspx?conf=jmp65&amp;page=dbvt&amp;url=https:\/\/wsw.com\/webcast\/jmp65\/dbvt\/1682208\" target=\"_blank\" rel=\"nofollow noopener\">ici<\/a> et sera \u00e9galement disponible sur la section \u00ab\u00a0\u00c9v\u00e9nements\u00a0\u00bb du site web \u00ab\u00a0Investisseurs\u00a0\u00bb de la Soci\u00e9t\u00e9\u00a0: <a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=CqOVkoeUxdzr9o458_9fq0LSE3J-ODB_jp9vSHGxzomt4fSprmHf8evXLMNA81KEKNXe-8ZEGEMpvoXdXI6MJ3hBJ8Uk-3K3X783yCbbL5CXGkjKrc2GrLX8uBDIrV2NvdwO0uPWij6El5aJXluFUcumWeP4us_KV1sX7EtPVR3k4xs2_uPlOR-GVFcA418j\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/dbv-technologies.com\/investor-overview\/events\/<\/a><\/p>\n<p align=\"justify\">Une rediffusion sera \u00e9galement disponible sur le site web de DBV Technologies pendant 90\u00a0jours apr\u00e8s l&rsquo;\u00e9v\u00e9nement.<\/p>\n<p align=\"justify\"><strong>\u00c0 propos de DBV Technologies<\/strong><br \/>\nDBV Technologies est une entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV Technologies se concentre actuellement sur l\u2019\u00e9tude de l\u2019utilisation de sa technologie exclusive, le patch VIASKIN<sup>\u00ae<\/sup>, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l\u2019anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e (EPIT\u2122), le patch VIASKIN<sup><sup>\u00ae<\/sup><\/sup>\u00a0est con\u00e7u pour dispenser des quantit\u00e9s de microgrammes d\u2019un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L\u2019EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l\u2019allergie sous-jacente d\u2019un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l\u2019allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s\u2019est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d\u2019allergies alimentaires. Les programmes d\u2019allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec le patch VIASKIN<sup><sup>\u00ae<\/sup><\/sup>\u00a0peanut chez les jeunes enfants (de 1 \u00e0 3 ans) et les enfants (de 4 \u00e0 7 ans) allergiques \u00e0 l\u2019arachide.<\/p>\n<p align=\"justify\">Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Ch\u00e2tillon, en France, avec des op\u00e9rations nord-am\u00e9ricaines bas\u00e9es \u00e0 Warren, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris (symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 (chacun repr\u00e9sentant cinq actions ordinaires) sont n\u00e9goci\u00e9s sur le Nasdaq Stock Market (symbole : DBVT ; CUSIP : 23306J309).<\/p>\n<p align=\"justify\">Pour plus d\u2019informations, veuillez consulter\u00a0<a title=\"www.dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=K3Vpho8rmgMS4wVST-lZhBQdYNIJGHjJXcJvxC3b8a0U3RLVcmIcgZnBCpskP0QZ2V0fzmZl6DYvEG51kQkx1lV-1e9-AdKzK2AKW3dBV3MEtWq2yOTFDAmM6Dd5js7BnqfUiCCo1b0ZoBAEZIdALguLv14OSy-xVCEjS-0nP7TC_F7MZ6i8h3EqoRqQYSStBnsSFyFK9wRkWxUykvMWFYzD_KOIuWrqxBHC-6jCXRON8mDzli5_EkB_Oq2ytmyuj4ntqAc0bi4lj553LcjG3looZmt7nQJqka-dbJ8DelP506_cnPZJnzjDEY5MJDSNZA1_Fbl-X4TujOiYpfbGbupH5XYxlGHSi8efKy9gL3aDdmz0Gin6F2MqJL2icvzOfXISkBQtgAdor24bzRJiqhs2mnS8HaHyCD7kOxmOf71H1KRKqI7Huw--VDM-zH5XSyELII0pP5VEOmA8oUvqn8ao0VRT2Nk3Ekn1WjZyY-El_m88CPQZ1GFY6eWKTf47OTfY9CYVzdHF9bMbwqaQq7a4fpjVLQkgCbr6xpQ1QhlfjXAuInz_kB15VLf2gDfGeQ4oFBkEz_YiWVuuJ_beQWO1cwDBFQRe_gWsDzzuXS77pjXZyQ-nSMHlGdsxIo02RUAuDz_rr1dq_mZxKLh3-a_XFyCB4TdExoOiw6xeU8xZtuGU-qB8Z9ocBTENmjBq6y_89Pi1-3jG0u7lHhpiV06tT6WK9lpKfCkSzGgpt3Fp3TxGncSiXti_ogW_bqbWUfIZ_IHyXiCa6-jKBAUdbxxp3lQHHyFnAu5tL3DWreq9x1DcIfxRVqIGOWxzRrYPevhiZG0WudqBumteTpLWyyS9LuMpfLOKa4tWZLShg2jT1UUIvmvpCS_ZN0xMuU4jmlMV0wL88E6dS1c5rEIXBCozswdf8-l-8ZzbkyVFFUJ3tylpa5MN5kwsgQx961y-oAN6IgEa4FKkgTCqQmJaoGxAXVGB6WrqtOPZW_jUqm_l1chVGDFzPyJT3Utap02zDnLbJ4G7yzZQFTXYLyWCcqvP86FMLiELQIDhDZkoFyI4ZNL3cXntUWn6e6lBrc54\" target=\"_blank\" rel=\"nofollow noopener\">www.dbv-technologies.com<\/a>\u00a0et nous contacter sur\u00a0<a title=\"X (anciennement Twitter)\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=_CfA51SK5QyE-Ql_hBUCd1nwfGTYHqS56FOKhy10cXnOIgc9FybNNKNJyKV5PfRAjXIAQkahGq_ZYBm2GfgGl6vpuDDF7pmGLc-kPX-AUDum9-Uz-Sy-2lxCTAuS7IaYiCS7mTqBlELaiRpj5hXE1N7tGrUfBTqSNBmxHeq_N50dI6ZgikZ4_eV_oEe0peTj1BQoxFZF8ZkZVx09CbBU3mlzhosBuX_iOTcDmsmboKpjnfBTSderhtQID08KluXVkKu8LGatbxgTAgIkipul3q4OX5O5D5pFVx5YXUu4KXAgNEMotRONXetC_ThEEwYQug6Hs0ZV0mtpxnck6q7IV0t2Urtf7zBDiJATURD5vK4-yn6-6Lfsy8QNB6etj-3_NRczQSEomIK0h01gbVw4tdqzAGVLiycq6JQY8gwWPIcH5BWHV3O_OetRAtPPJHqjE9nnxEK51b927IANiqy21OJoPGgutFmlx2q8Ezc9H8fPXZAHaU5PbUPErUZ0EGVV-AqciFxKn4qaTJ-ohme5SXgGnvcr5QL8n1IvgOrEy8z0WBD74XKzGj8wuPsnoJl25ivXVu6h21XI1QCQ4m51-B1H_GVEN001vpeOReTNeqM6lHcvYmL_-QB8g5ZTOSx25kXXJBWT1rKnVc3p7zMaVux7RllgNHgESBKQsuJgHwl-KS2LuZ_mbsx13nlwsvpMxKMJJktqSRvS-O2rO8CkAjFr-mQpQXHQn8IByZFhPQbqIQaZz19t8dYdV72SB0V9mCunVZu_hMRd-b-A7PGie05SvLsXAlS3DNRpXHKiRY3u3QIyOVGDwqkUCz7ysggK3Z3daZRra0Y-vwmv4NSgfV4iDwRRM7GYA7WdrZpN7lLTWuH1mH1c7WgjlvmEpmsvtVffHcmralPU8LfPneJJNB5tIXVaw3wuqQpamR0gKIEXJHhsnM2SNEryms0BWue7PfNoVCf86v2VoYq3Q8oQVs7HVUbMO8-QHaXfCzkITqgCDlUfoWag6cM6iXKaexraq0d_EACJ9HFKVfW1HwQat9pH1y9bs9uUunIdOqSk4HAF02ga4W8T3GrYdECGNsSQ\" target=\"_blank\" rel=\"nofollow noopener\">X (anciennement Twitter)<\/a>\u00a0et\u00a0<a title=\"LinkedIn.\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=EPEkzr_wn0_jyYVDor7Xzb_2AldhyElp-bX8xA1B-EKd2eW3fJs00j1pRo1ZQr7CM4BsmWmZIDWZqaV1l1aPcbxE-JauLxJAWzITyYr_zq0amgFkzuoZinKaU5M_Y9F5MoO1V8f8ztjaF23u5qXGdbzAU1ZERtAkikGaAqGuBctiVQm8D8CCTmcVEaMND4S1ma1NGola5uGIV1bro-vRTRpaWSAVA__dJqopfVxuBnOh_WW7oAzMPvFevoj96le-vVqOw-KhGEnCXPOnQPukWldccYQdWXaTOdNU4Vo-LsH-HgcBf_06Rog7-oAb-O3ZnHIHn29nz_IIVIpxtnNe0vjVRPx9HFmT9RFk6l9SE5CVCL7ORW6vvTc4fK9xjz_ATvuCcpwP7E0MSPqqrM7tSXbesyP4d85UiIl0lVCjCgsctvbLQLqGgtd2b3KGvDz18FuErbGG5CIZuRIsaxiqllU3x4xAw-h0YDxNTmzASjl1Dv2LuJHYjzVK1rKDShU-UBeXYVSlXowsr9pgjU_Xs1_76YXWJkNg2mQn_pB6rH30PzdzRvZ83e30zunZHnP_dwQu8Rn2tYoqh67sq1IXYUyvVQV7w5vRxhQS6n98XV4h0Ge3dFgmQbt3s4txlNJJAkEIft_D0lNu9ONI0LJvgmAD_OpiNZmmnuR-mD3W1DA93eHXjRV8FJw1xzzUoNL0hSvxw65m_o2U2llj1DNCG1N3n3EfkRayG65rPhJAzcsckD0gAQT8pxmvTWvcv2Tj_dl-L5XcVi1i6-EYEj6Xyvzo8UStwwyFO3FpuzNjQleNA3WC7T9hVOYRRz0vs5A8bpiSDi5NETxqoX_Inv8UHeyEA9ZMxYMW0vijY2H1APz8J9HuV6nM1J6TU2LDLyTxG98WDH9ALzpdf_B00b1WWOO_u__wiLEGovCDonRc6bhCcSoNSNrR8UQjuLNsc_UOuWZfYEIVZ-MAtnlFYnMAW0iYSdaI9t8RnBihpFd_jmcdO49-mYe-TEk0o5y4bk9V2Ixx96IyIaXwJ0HknDdSwQ==\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn.<\/a><\/p>\n<p align=\"justify\"><strong>Contact avec les investisseurs <\/strong><br \/>\nKatie Matthews<br \/>\nDBV Technologies<br \/>\n<a title=\"katie.matthews@dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=APoiNe4VO0V5rbUa2xlchVpnvfaEMYUmHmSg1ftI1INijOLTGRSvtWcdXPP1PaU0uEeeMBzs0tIazNApAkDAA9Zb6LBkuTK5bO-dPqnt6dt9fkRkzEr8JwwwduTaP5RiqO3EnX1mBTrg_35Z5O1ySg==\" target=\"_blank\" rel=\"nofollow noopener\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>\nAngela Marcucci<br \/>\nDBV Technologies<br \/>\n<a title=\"angela.marcucci@dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=qdFvoepWH0wnF64vBeL44HQpAufhfUoZ0k_w0frLBbf8JVY1TYG2FfOnnpmHuqLfT5qrl6oNFMYv299LKVE2TXXNx642ZbttqqbK4qGdlPmVixj9AsKOYTBdxvAhMKOSEm1UkEC9gw8Bww9ivE5dUg==\" target=\"_blank\" rel=\"nofollow noopener\">angela.marcucci@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\"><strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li><a title=\"version PDF\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=IBWNdUedmnwu_Db10cZNS3ohmrb79T-7FWu1ciqHol9HrbLNewDFssQuKVJo-vWJhaO5lDatg92poKoQXoMXnlgLi9tauF4TcS2DonTX2uT-kVFkDycGhBcILo4ixve-RM-E6oDu_mQ_TZgVbid6YBzwpR-0UeB7QHsFCqUHYZ4=\" target=\"_blank\" rel=\"nofollow noopener\">version PDF<\/a><\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/MmY1OTMxNjUtNmE4NS00YmMyLThlOGQtYjgzMDg1Y2Y1MGRmLTEwMTExNTItMjAyNS0wNS0wNS1mcg==\/tiny\/DBV-Technologies-S-A-.png\" alt=\"\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" \/><\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-22073","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/22073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/22073\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=22073"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=22073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}